Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket

The commenter opposes the FDA's decision to block specific bulk drug substances, arguing that it unfairly penalizes reputable companies while failing to address unregulated entities. They express concern over pharmaceutical industry influence on regulations and suggest the FDA should focus on enforcement against unsafe actors rather than restricting regulated suppliers.

The commenter opposes the proposed restrictions on bulk drug substances, arguing that the decision is based on "paid influence" from pharmaceutical companies rather than scientific evidence. They claim that the peptides in question have very few side effects and request that the agency consult with experts in the field before reversing the decision.

The commenter opposes the proposed action, arguing that it unfairly targets peptides which they claim are safe, natural, and affordable medical treatments. They contend that the FDA lacks clinical evidence of harm for these substances and suggest the move is an attempt to remove products from the market for financial reasons rather than public safety.

The commenter opposes the potential ban or reclassification of peptides, arguing that they are affordable and improve the quality of life for many patients. They claim the action is driven by "big pharma" lobbying and greed rather than public health concerns.

The commenter opposes the proposed action, arguing that it is a "witch hunt" designed to favor pharmaceutical companies and eliminate competition from compounded medicines. They state that they have personally benefited from compounded drugs and believe removing these substances would be harmful to patients.